Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
Results of well-controlled prospective clinical trials showed the efficacy of lipid-lowering therapies in the reduction of cardiovascular (CV) events in western populations, but they were not reported with a Chinese population. This multicenter study was conducted to determine the effects of Xuezhikang (XZK), a partially purified extract of red yeast rice, on lipoprotein and CV end points in Chinese patients who experienced a previous myocardial infarction. Nearly 5,000 of these patients with average low-density lipoprotein cholesterol levels at baseline were randomly assigned either to placebo or to XZK daily for an average of 4.5 years. The primary end point was a major coronary event that included nonfatal myocardial infarction and death from coronary heart disease. Frequencies of the primary end point were 10.4% in the placebo group and 5.7% in the XZK-treated group, with absolute and relative decreases of 4.7% and 45%, respectively. Treatment with XZK also significantly decreased CV and total mortality by 30% and 33%, the need for coronary revascularization by 1/3, and lowered total and low-density lipoprotein cholesterol and triglycerides, but raised high-density lipoprotein cholesterol levels. In conclusion, long-term therapy with XZK significantly decreased the recurrence of coronary events and the occurrence of new CV events and deaths, improved lipoprotein regulation, and was safe and well tolerated.
1689-1693
Lu, Z.
e92770ea-27bf-4223-9b37-5a545e956a04
Kou, W.
9be5ed72-2f7f-4236-81be-1e04d3f1c9e7
Du, B.
c76992e7-ad88-4736-a53a-e00fea4a13b1
Wu, Y.
84854e37-ada6-4cc8-995f-6ce5ebc77423
Zhao, S.
22859638-9172-4d43-96fd-08a652aaa3fd
Brusco, O.A.
b4815697-7c74-470f-8a96-b8562357dd01
Morgan, John M.
ac98099e-241d-4551-bc98-709f6dfc8680
Capuzzi, D.M.
b58747aa-f3e6-4dbf-a3da-3eae534d47b7
Li, S.
be6d14e4-0c49-47a8-a6e0-1c99a64e1024
2008
Lu, Z.
e92770ea-27bf-4223-9b37-5a545e956a04
Kou, W.
9be5ed72-2f7f-4236-81be-1e04d3f1c9e7
Du, B.
c76992e7-ad88-4736-a53a-e00fea4a13b1
Wu, Y.
84854e37-ada6-4cc8-995f-6ce5ebc77423
Zhao, S.
22859638-9172-4d43-96fd-08a652aaa3fd
Brusco, O.A.
b4815697-7c74-470f-8a96-b8562357dd01
Morgan, John M.
ac98099e-241d-4551-bc98-709f6dfc8680
Capuzzi, D.M.
b58747aa-f3e6-4dbf-a3da-3eae534d47b7
Li, S.
be6d14e4-0c49-47a8-a6e0-1c99a64e1024
Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O.A., Morgan, John M., Capuzzi, D.M. and Li, S.
(2008)
Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
The American Journal of Cardiology, 101 (12), .
(doi:10.1016/j.amjcard.2008.02.056).
Abstract
Results of well-controlled prospective clinical trials showed the efficacy of lipid-lowering therapies in the reduction of cardiovascular (CV) events in western populations, but they were not reported with a Chinese population. This multicenter study was conducted to determine the effects of Xuezhikang (XZK), a partially purified extract of red yeast rice, on lipoprotein and CV end points in Chinese patients who experienced a previous myocardial infarction. Nearly 5,000 of these patients with average low-density lipoprotein cholesterol levels at baseline were randomly assigned either to placebo or to XZK daily for an average of 4.5 years. The primary end point was a major coronary event that included nonfatal myocardial infarction and death from coronary heart disease. Frequencies of the primary end point were 10.4% in the placebo group and 5.7% in the XZK-treated group, with absolute and relative decreases of 4.7% and 45%, respectively. Treatment with XZK also significantly decreased CV and total mortality by 30% and 33%, the need for coronary revascularization by 1/3, and lowered total and low-density lipoprotein cholesterol and triglycerides, but raised high-density lipoprotein cholesterol levels. In conclusion, long-term therapy with XZK significantly decreased the recurrence of coronary events and the occurrence of new CV events and deaths, improved lipoprotein regulation, and was safe and well tolerated.
This record has no associated files available for download.
More information
Published date: 2008
Identifiers
Local EPrints ID: 183301
URI: http://eprints.soton.ac.uk/id/eprint/183301
ISSN: 0002-9149
PURE UUID: cfe62791-7690-4a84-b397-6e6d17b63209
Catalogue record
Date deposited: 03 May 2011 10:22
Last modified: 10 Jul 2024 17:04
Export record
Altmetrics
Contributors
Author:
Z. Lu
Author:
W. Kou
Author:
B. Du
Author:
Y. Wu
Author:
S. Zhao
Author:
O.A. Brusco
Author:
John M. Morgan
Author:
D.M. Capuzzi
Author:
S. Li
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics